Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence Fong

Showing results (171-180 of 198) with videos related to

Pageof 20
Sort By:
European Urology|March 8, 2021
Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical TrialThomas Powles, Michael B Atkins, Bernard Escudier, et al.
Journal for Immunotherapy of Cancer|June 20, 2020
Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancerAnanth Annapragada, Andrew Sikora, Catherine Bollard, et al.
Bioconjugate Chemistry|November 11, 2017
Imaging PD-L1 Expression with ImmunoPETCharles Truillet, Hsueh Ling J Oh, Siok Ping Yeo, et al.
Clinical Genitourinary Cancer|June 14, 2023
Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab VedotinTanya Jindal, Li Zhang, Prianka Deshmukh, et al.
Journal of the National Cancer Institute|October 16, 2018
The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic TargetShuang G Zhao, Jonathan Lehrer, S Laura Chang, et al.
Journal for Immunotherapy of Cancer|January 2, 2023
Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinomaMeenal Sinha, Courtney Betts, Li Zhang, et al.
Nature Medicine|July 10, 2023
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim resultsMartin Gutierrez, Wei-Sen Lam, Matthew D Hellmann, et al.
Journal for Immunotherapy of Cancer|June 4, 2021
Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastomaErin F Simonds, Edbert D Lu, Oscar Badillo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2020
Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent MelanomaAlain P Algazi, Christopher G Twitty, Katy K Tsai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2025
Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate CancerMatthew D Galsky, Karen A Autio, Christopher R Cabanski, et al.
Pageof 20

Showing results (171-180 of 198) with videos related to

Sort By:
Pageof 20
European Urology|March 8, 2021
Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical TrialThomas Powles, Michael B Atkins, Bernard Escudier, et al.
Journal for Immunotherapy of Cancer|June 20, 2020
Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancerAnanth Annapragada, Andrew Sikora, Catherine Bollard, et al.
Bioconjugate Chemistry|November 11, 2017
Imaging PD-L1 Expression with ImmunoPETCharles Truillet, Hsueh Ling J Oh, Siok Ping Yeo, et al.
Clinical Genitourinary Cancer|June 14, 2023
Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab VedotinTanya Jindal, Li Zhang, Prianka Deshmukh, et al.
Journal of the National Cancer Institute|October 16, 2018
The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic TargetShuang G Zhao, Jonathan Lehrer, S Laura Chang, et al.
Journal for Immunotherapy of Cancer|January 2, 2023
Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinomaMeenal Sinha, Courtney Betts, Li Zhang, et al.
Nature Medicine|July 10, 2023
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim resultsMartin Gutierrez, Wei-Sen Lam, Matthew D Hellmann, et al.
Journal for Immunotherapy of Cancer|June 4, 2021
Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastomaErin F Simonds, Edbert D Lu, Oscar Badillo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2020
Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent MelanomaAlain P Algazi, Christopher G Twitty, Katy K Tsai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2025
Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate CancerMatthew D Galsky, Karen A Autio, Christopher R Cabanski, et al.
Pageof 20